Literature DB >> 11150443

Management of cholelithiasis in pediatric patients who undergo bone marrow transplantation.

S D Safford1, K M Safford, P Martin, H Rice, J Kurtzberg, M A Skinner.   

Abstract

PURPOSE: The aim of this study was to determine the incidence, risk factors, and proper management for asymptomatic cholelithiasis in children undergoing bone marrow transplantation (BMT).
METHODS: The authors reviewed retrospectively the records of 575 children who underwent bone marrow transplantation at a University bone marrow transplantation unit (BMT) unit between February 1991 and October 1999. Of these patients, 235 underwent abdominal ultrasonography for evaluation of jaundice, sepsis, abdominal pain, or metastasis. To identify risk factors for cholelithiasis, the authors stratified the patients based on their disease and treatment regimen. Finally, the authors analyzed the natural history and management of BMT children with cholelithiasis.
RESULTS: The authors identified 20 cases of cholelithiasis (8.5%) in the 235 BMT patients who underwent ultrasonography. Children who underwent BMT to treat bone marrow failure showed a significantly increased risk of cholelithiasis compared with children treated for malignancy (27% v 7.4%; P<.01). Most children (85%) with gallstones did not require surgical intervention. Specifically, 9 (45%) died from their primary disease, 5 (25%) showed sonographic resolution of their gallstones, and 3 (15%) underwent follow-up nonoperatively with persistent cholelithiasis. Three of the 20 patients with gallstones (15%) had signs of acute cholecystitis and underwent surgery. There were no surgical complications or deaths in the operative group.
CONCLUSIONS: Cholelithiasis occurs at a high incidence in pediatric bone marrow transplant patients. Children undergoing BMT for bone marrow failure are at higher risk of having gallstones than those being treated for malignancy. Finally, these data support a strategy of nonoperative management for asymptomatic cholelithiasis in this highly selected group of patients.

Entities:  

Mesh:

Year:  2001        PMID: 11150443     DOI: 10.1053/jpsu.2001.20016

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  5 in total

1.  Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Authors:  Bryan V Dieffenbach; Nan Li; Arin L Madenci; Andrew J Murphy; Dana Barnea; Todd M Gibson; Emily S Tonorezos; Wendy M Leisenring; Rebecca M Howell; Lisa R Diller; Qi Liu; Eric J Chow; Gregory T Armstrong; Yutaka Yasui; Kevin C Oeffinger; Christopher B Weldon; Brent R Weil
Journal:  Eur J Cancer       Date:  2020-05-15       Impact factor: 9.162

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

3.  Gallstones in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up.

Authors:  Paul A Hoffmeister; Barry E Storer; George B McDonald; K Scott Baker
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

Review 4.  Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group.

Authors:  Sharon Castellino; Andrew Muir; Ami Shah; Sheila Shope; Kevin McMullen; Kathy Ruble; Ashley Barber; Andrew Davidoff; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

5.  Complex profile of multiple hepatobiliary and gastrointestinal complications after hematopoietic stem cell transplantation in a child with Nijmegen breakage syndrome.

Authors:  Przemysław Gałązka; Krzysztof Czyżewski; Anna Szaflarska-Popławska; Robert Dębski; Anna Krenska; Jan Styczyński
Journal:  Cent Eur J Immunol       Date:  2019-09-30       Impact factor: 2.085

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.